Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Muscle Invasive Bladder Urothelial Carcinoma 1

Interventions

Specimen Handling 125pembrolizumab 123Magnetic Resonance Spectroscopy 108Carboplatin 89Cyclophosphamide 80Biopsy 69Cisplatin 67Paclitaxel 61Bevacizumab 56Gemcitabine 54Nivolumab 49fludarabine 48Dexamethasone 41Rituximab 39Pemetrexed 39Fluorouracil 39Radiotherapy 37Doxorubicin 37atezolizumab 36Docetaxel 36Leucovorin 35Oxaliplatin 32Capecitabine 32venetoclax 31Temozolomide 29Prednisone 29durvalumab 27Standard of Care 27Radiation 27Letrozole 27

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Circulating Tumor DNA × 30 days × Clear all
NCT05987241 2026-06-03

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

National Cancer Institute (NCI)

Phase 2/3 Recruiting
992 enrolled
Genitourinary

Muscle Invasive Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡